Takeover-driven resurgence fails to materialize for biotech

Those hoping for a string of buyouts to tempt investors back into biotech will be disappointed by the opening months of 2022. Transaction volume fell to a five-year low in the first quarter, while the sums involved were only rescued by two big joint-venture deals in the biosimilars space.